<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03970850</url>
  </required_header>
  <id_info>
    <org_study_id>CTNG-01-18NMD</org_study_id>
    <nct_id>NCT03970850</nct_id>
  </id_info>
  <brief_title>NeuMoDx PrEDiCTiNG Study Evaluation Plan</brief_title>
  <official_title>Multi-Center Clinical Performance Evaluation of the NeuMoDx™ Chlamydia Trachomatis (CT) / Neisseria Gonorrhoeae (NG) [CT/NG] Assay on the NeuMoDx™ 288 Molecular System and the NeuMoDx™96 Molecular System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuMoDx Molecular, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NAMSA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>NeuMoDx Molecular, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This investigational study will be conducted to evaluate the performance of the NeuMoDx™
      CT/NG Assay on the NeuMoDx™ 288 Molecular System and NeuMoDx™ 96 Molecular System
      (collectively referred to as NeuMoDx™ CT/NG Assay test system).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clinical performance characteristics of the NeuMoDx CT/NG Assay on NeuMoDx™ 288 Molecular
      System and NeuMoDx™ 96 Molecular System will be evaluated in a multi-center, prospective,
      sampling study by comparing the diagnoses made by the NeuMoDx™ CT/NG Assay to Patient
      Infected Status (PIS) as the reference standard.

      Prospectively collected urine and swab specimens from individual subjects will be tested
      using the NeuMoDx™ CT/NG Assay at one of the three NeuMoDx testing sites. Subjects' PIS for
      CT and PIS for NG will be determined by a central laboratory using FDA-cleared, legally
      marketed CT/NG combo assays on pre-specified sample matrices according to the PIS
      determination algorithms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Actual">February 25, 2020</completion_date>
  <primary_completion_date type="Actual">February 25, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical specificity and sensitivity</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Clinical specificity and sensitivity of NeuMoDx CT/NG Assay for both CT and NG relative to an individual's patient infected status (PIS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Valid results rate</measure>
    <time_frame>Through study completion, an average of 1 year</time_frame>
    <description>Evaluate indeterminate and unresolved rates</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">4017</enrollment>
  <condition>Chlamydia Trachomatis Infection</condition>
  <condition>Neisseria Gonorrheae Infection</condition>
  <arm_group>
    <arm_group_label>Multi-arm - Symptomatic and Asymptomatic Males</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 1 - Urine from males subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-arm - Symptomatic and Asymptomatic Females</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 2 - Endocervical, self-collected (in the clinical setting) and physician-collected vaginal swabs and urine from female subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multi-arm - FDA cleared NAATs (Comparator)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Arm 3 - Comparator (for females - vaginal and urine NAATs and for males - 3 urine NAATs)</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>NeuMoDx CT/NG Assay</intervention_name>
    <description>NeuMoDx CT/NG Assay as implemented on NeuMoDx 288 Molecular System and NeuMoDx 96 Molecular System</description>
    <arm_group_label>Multi-arm - Symptomatic and Asymptomatic Females</arm_group_label>
    <arm_group_label>Multi-arm - Symptomatic and Asymptomatic Males</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>FDA-cleared NAATs</intervention_name>
    <description>Testing swabs and urine specimen from both male and female subjects on the FDA-cleared NAATs</description>
    <arm_group_label>Multi-arm - FDA cleared NAATs (Comparator)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male and female subjects of at least 14 years of age or older.

          2. Subject must be able and willing to provide informed consent. The use of a 'surrogate'
             or 'Legally Authorized Representative' is allowed and shall follow the site's standard
             procedures, under which the clinical investigation will be conducted.

          3. Subjects undergoing a routine pelvic examination, subjects eligible for screening
             evaluations for possible STDs and/or subjects known to be partners with a person with
             a confirmed or suspected STD.

          4. Subject is willing to provide all required specimens.

        Exclusion Criteria:

          1. Female subject reports that she had a hysterectomy.

          2. Subject self-reports use of antibiotics within 28 days of study enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Subjects eligible for CT/NG screening (make sure it matches the protocol)</gender_description>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Healthcare Clinical Date, Inc. (Segal Trials)</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Southwest and Central Florida</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Southwest and Central Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33617</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University (IU)</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LSU Health Science</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NeuMoDx Molecular, Inc.</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System (HFHS)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Northern, Central and Southern New Jersey</name>
      <address>
        <city>Delran</city>
        <state>New Jersey</state>
        <zip>08075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Northern, Central and Southern New Jersey</name>
      <address>
        <city>Elizabeth</city>
        <state>New Jersey</state>
        <zip>07201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Northern, Central and Southern New Jersey</name>
      <address>
        <city>Newton</city>
        <state>New Jersey</state>
        <zip>07860</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriCore Reference Labs</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina (MUSC)</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Planned Parenthood - Gulf Coast</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.cdc.gov/nchhstp/newsroom/2018/press-release-2018-std-prevention-conference.html</url>
    <description>STD Prevention Conference - Press Release. New CDC analysis shows steep and sustained increases in STDs in recent years. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention</description>
  </link>
  <link>
    <url>https://www.cdc.gov/std/tg2015/tg-2015-print.pdf</url>
    <description>Sexually Transmitted Diseases Treatment Guidelines, 2015. Centers for Disease Control and Prevention MMWR. 2015 June 5 Vol. 64. No. 3.</description>
  </link>
  <link>
    <url>https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm</url>
    <description>Chlamydia - CDC Fact Sheet (Detailed). 2016 October 4, [cited 2019 January 3]</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>June 11, 2020</last_update_submitted>
  <last_update_submitted_qc>June 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Chlamydia Infections</mesh_term>
    <mesh_term>Gonorrhea</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

